C21 Investments Inc. CWLXF
Annual
Quarterly
FY2026 · ended Mar 31, 2026 · Revenue $32.61M, +8.3% YoY · Filed Jun 12, 2026
C21 Investments Inc. (CWLXF) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $32.6 million and a net loss of $3.2 million. Free cash flow was $1.1 million. As of Mar 31, 2026 it held $2.2 million in cash and investments and $9.8 million in total debt.
Revenue
$32.61M
+8.3% vs prior year
Net income
$-3.24M
+18.3% vs prior year
Operating cash flow
$1.36M
-0.2% vs prior year
Free cash flow
$1.12M
+16.6% vs prior year
EPS
$-0.03
+0.0% vs prior year
Dividend per share
None
Shares outstanding
117.84M
-0.1% vs prior year
Net cash
$-7.54M
FY 2026
Operating margin
7.0%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- CWLXF (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 831609
- Former names
- CURLEW LAKE RESOURCES INC (until Nov 29, 2012); CURLEW LAKE RESOURCES INC /FI (until Jan 3, 2007)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Jan 31, 2024 |
FY 2023 Jan 31, 2023 |
FY 2022 Jan 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $32.6M | $30.1M | $28.3M | $28.9M | $33.0M |
| Operating income | $2.3M | $1.3M | $1.5M | $4.0M | $9.8M |
| Net income | -$3.2M | -$4.0M | -$3.3M | $293,211 | $10.0M |
| Diluted EPS | -$0.03 | -$0.03 | -$0.03 | $0.00 | $0.08 |
| Operating cash flow | $1.4M | $1.4M | $3.3M | $6.0M | $8.4M |
| Free cash flow | $1.1M | $958,920 | $2.7M | $5.5M | $5.9M |
| Total assets | $54.4M | $57.0M | $54.5M | $58.3M | $61.8M |
| Total liabilities | $29.0M | $28.3M | $23.5M | $24.0M | $28.1M |
| Stockholders' equity | $25.4M | $28.7M | $31.0M | $34.3M | $33.7M |
| Cash and investments | $2.2M | $2.6M | $2.4M | $1.9M | $3.1M |
| Total debt | $9.8M | $10.3M | $9.6M | $9.0M | $9.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Aug 21, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 10, 2026 | Aug 7, 2026 |
| 6-K | Current report (foreign issuer) | Jul 9, 2026 | Aug 7, 2026 |
| 6-K | Current report (foreign issuer) | Jun 22, 2026 | Jun 19, 2026 |
| 6-K | Current report (foreign issuer) | Jun 15, 2026 | Jun 15, 2026 |
| 20-F | Annual report (foreign issuer) | Jun 12, 2026 | Mar 31, 2026 |
All 310 C21 Investments Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.